BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (March 2017)

26 slides from BioSpecifics Technologies's investor presentation, Mar 6, 2017

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    PP. > a ‘é \ a? < — Innovators in the development & commercialization of: INJECTABLE « COLLAGENASE c A = @ . BioSpecifics March 2017

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding

  3. Slide 3: Company Overview

    Company Overview (NASDAQ: BSTC Originator of collagenase based-therapies Positive clinical results for XIAFLEX reported in 12 indications to date Profitable biopharma company with lean corporate structure and stock buy-back program Receives revenues from XIAFLEX® milestones, royalties on net sales,

  4. Slide 4: Pipeline

    XIAFLEX® Pipeline Approved Indications endo Dupuytren’s Contracture Peyronie's Disease endo endo Initiate Phase 3 in 2H17 Cellulite Endo is currently performing a ‘commercial assessment Endo is currently performing a Human Lpoma , > Cll et Adhesive Capsulitis endo — Endo is currently performing a Ca

  5. Slide 5: Marketed XIAFLEX Indications

    Marketed XIAFLEX Indications: Dupuytren’s Contracture & Peyronie’s Disease

  6. Slide 6: XIAFLEX 4Q and Full Year 2016 Net Revenues

    XIAFLEX 4Q and Full Year 2016 Net Revenues 4Q16 net revenues were $55.5M vs. $50.2M, a 11% growth Full year 2016 net revenues were $189.7M vs. $158.1M for 2015, a 20% growth Source: Endo International ple

  7. Slide 7: XIAFLEX Future Growth Opportunities

    XIAFLEX Future Growth Opportunities Endo expects high-single to low-double-digit revenue growth in 2017 Sizable opportunity for growth Of the patients diagnosed with Peyronie’s disease, 85-90% are untreated and for Dupuytren’s contracture 75-80% are untreated Paladin began promoting XIAFLEX in Canad

  8. Slide 8: Dupuytren's Contracture

    XIAFLEX® for Dupuytren’s Contracture Definition & Key Complications Deforming condition of the hand in which one or more fingers contracts toward the palm Limits range of motion and impairs quality of life Affects between 3-9% of adult Caucasians Post-treatment: Pre-treatment: Source: Endo Internati

  9. Slide 9: Peyronie's Disease

    XIAFLEX® for Peyronie’s Disease Definition & Key Complications Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable plaque, penile deformity and erectile dysfunction Potential loss of self

  10. Slide 10: Pipeline Indications

    XIAFLEX® Pipeline Indications

  11. Slide 11: Uterine Fibroids

    XIAFLEX® for Uterine Fibroids Phase 1 Trial to Begin in 1Q17 Benign tumors in the reproductive tract that contain large amounts of collagen Definition & Key Cause pelvic discomfort and pain, decreased fertility, pregnancy Complications complications, increased rate of miscarriage, heavy menstrual bl

  12. Slide 12: Uterine Fibroids Phase 1 Trial Design

    XIAFLEX® for Uterine Fibroids Phase 1 Trial Design Open-label dose escalation Phase 1 study in 15 female subjects treated prior to hysterectomy at the Department of Gynecology & Obstetrics at Johns Hopkins University 3 subjects to receive saline and 12 to receive 3 increasing dose levels of XIAFLEX

  13. Slide 13: Cellulite

    XIAFLEX® for Cellulite OVERVIEW Skin dimpling as a result of collagen fibrous septae, occurring mainly on the buttocks, lower limbs, and abdomen Affects ~85-98% of post-pubertal females Highly Statistically Significant Positive Results from Phase 2b Study Anatomy of Cellulite Cette gerpies Subject A

  14. Slide 14: Cellulite Phase 2b Top-line Data

    XIAFLEX® for Cellulite Highly Statistically Significant Top-line Data from Phase 2b Study 375 women with moderate or severe cellulite (18+ years) Up to 3 treatment sessions of 0.84 mg/session or placebo (12 injections per session) with each treatment session occurring 21 days apart Primary endpoint

  15. Slide 15: Adhesive Capsulitis

    XIAFLEX® for Adhesive Capsulitis Potential to be Only FDA Approved Nonsurgical Therapy Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder * Common available treatment options are often painful and can require anesthesia * Long-term intensive physical t

  16. Slide 16: Phase 2b Study Results of XIAFLEX in Adhesive Capsulitis

    Phase 2b Study Results of XIAFLEX' in Adhesive Capsulitis/Frozen Shoulder Syndrome Phase 2a Results 321 patient double-blind, placebo-controlled study evaluating safety and efficacy in Stage 2 (frozen stage) de unilateral idiopathic frozen shoulder +0 Primary endpoint: change in degrees from baselin

  17. Slide 17: Human Lipomas

    XIAFLEX® for Human Lipomas Potential to be Only FDA-Approved Pharmaceutical Therapy U.S. Market Opportunity Phase 2 Trial Design Encapsulated deposits of benign fat, often detected as bulges under the skin No FDA-approved pharmaceutical therapies available Offers an alternative to patients that may

  18. Slide 18: Positive Top-Line Phase 2 Study Results

    Positive Top-Line Phase 2 Study Results Single 0.58 mg Injection of XIAFLEX Primary endpoint: 81.3% reduction in visible surface area for XIAFLEX vs. 2.1% increase for placebo; 83.4% difference in favor of XIAFLEX (p<0.0001) 89.5% responder rate (showed a 250% decrease in lipoma visible surface area

  19. Slide 19: Lateral Hip Fat

    XIAFLEX® for Lateral Hip Fat Definition & Complications Similar prevalence to cellulite Fat accumulation is common among woman particularly as they age = Often very difficult to improve its appearance through exercise and diet alone Patients frequently avoid exercise and are unable to restrict their

  20. Slide 20: Plantar Fibromatosis

    XIAFLEX® for Plantar Fibromatosis Definition & Complications ~200,000 patients in the U.S. Pain and disability caused by the thickening of the feet's deep connective tissue Formation of nodules or cords along tendons of the foot Patients often have Dupuytren’s disease, Peyronie’s disease and adhesiv

  21. Slide 21: Additional Promising Unlicensed Indications

    Additional Promising Unlicensed Indications Capsular Contracture, Breast Hypertrophic Scars & Keloids Dercum’s Disease Knee Arthrofibrosis Urethral Strictures Source: Endo international ple Post-surgical complication that can deform the breast and cause pain Scars that form on the skin at site of in

  22. Slide 22: Endo Partnership for Development and Commercialization of XIAFLEX

    Endo Partnership for Development and Commercialization of XIAFLEX® >$101.7M Received as of September 30, 2016 $101.7M received in licensing, sublicensing, milestone, COGS, and royalty payments as of September 30, 2016 Low double digit royalties as % of net sales Future Payments Additional mark-up on

  23. Slide 23: Strong IP Portfolio

    Strong IP Portfolio Long-term patent protection for XIAFLEX Dupuytren’s Contracture Biologic Exclusivity until 2022 Drug product composition patent until 2028 Peyronie’s Disease Orphan Drug protection in U.S. until 2020 Drug product composition patent until 2028 Patents and Patent Applications Owned

  24. Slide 24: Consistently Profitable Annually

    Consistently Profitable Annually Financial Highlights (unaudited) For the nine months ended 09/30/16 09/30/15 7 Cash and equivalents, and investments $51,266,414 $ 32,824,471 Income Statement Revenues $19,630,307 $16,611,268 Other income 238,152 65,056 Costs and expenses (6,915,669) (6,062,469) Prov

  25. Slide 25: Anticipated Upcoming Pipeline Milestones

    Anticipated Upcoming Pipeline Milestones Cosmetic and Other Indications C1 Initiate Phase 3 clinical trial in 2H17 C1 Publication of full Phase 2b data Cellulite Other Indications C1 Analysis of additional indications and priority programs ongoing BIOSPECIFICS: Medically Necessary Indi Uterine Fibro

  26. Slide 26: Innovators in the development & commercialization of injectable collagenase

    _— — EE e \ a? - Innovators in the development & commercialization of _ INJECTABLE COLLAGENASE ert “——~e ° BioSpecifics March 2017

BioSpecifics Technologies — Investor Presentation (March 2017) on 6ix